Showing 1 - 6 results of 6 for search 'Panos Kefalas', query time: 0.02s Refine Results
  1. 1
    Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test

    Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test by Jesper Jørgensen, Panos Kefalas

    Published 2017-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate

    Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate by Jesper Jørgensen, Panos Kefalas

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries

    Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries by Jesper Jørgensen, Eve Hanna, Panos Kefalas

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching

    Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching by Jesper Jørgensen, Laura Mungapen, Panos Kefalas

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease

    The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’... by Jesper Jørgensen, Spiros Servos, Panos Kefalas

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

    Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy by Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: